# US 7,744,926 B2 · Use of a biologically active blood serum for the treatment of stroke > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,744,926 B2 - Document ID: US7744926B2 - Status: Granted - Kind: B2 - Application number: 11/404,971 - Filed: 2006-04-14 - Published: 2006-11-16 - Granted: 2010-06-29 - Earliest claimed: 2005-04-18 - Assignees: Owen Holding Ltd. - Inventors: Vitali A. Shestakov - Web page: https://patentgrep.com/patent/US7744926B2 ## CPC - A61L 2/081: Gamma radiation - A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51) - A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61L 2103/05: Living organisms or biological materials - A61L 2103/09: Blood or products thereof - A61N 1/36014: {External stimulators, e.g. with patch electrodes (external pacemakers A61N1/3625)} - A61N 1/3605: {Implantable neurostimulators for stimulating central or peripheral nerve system} - A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) ## Abstract The present invention relates to the use of a pharmacologically active blood serum product producible by a method comprising electrostimulation of a non-human animal, withdrawal of blood from said animal, isolation of serum from said blood, and gamma irradiation of said serum in the treatment of stroke, preferably ischemic stroke. ## Claims ### Claim 1 A method for treating stroke wherein said method comprises administering, to a subject in need of such treatment, a biologically active blood serum made by a method comprising the steps of: a) electrostimulation of a non-human animal, b) withdrawal of blood from said animal, c) isolation of serum from said blood, and d) gamma irradiation of said serum. ### Claim 2 (depends on 1) The method according to claim 1, wherein the non-human animal is selected from the group consisting of mammals and birds. ### Claim 3 (depends on 2) The method according to claim 2, wherein the bird is selected from the group consisting of chicken, duck, goose, ostrich, and quail. ### Claim 4 (depends on 1) The method according to claim 1, wherein in step a) the head, the neck, the body and/or one or more limbs is electro stimulated. ### Claim 5 (depends on 1) The method according to claim 1, wherein the electro stimulation is carried out for a time period of between 1 and 60 seconds. ### Claim 6 (depends on 1) The method according to claim 1, wherein the electro stimulation is carried out with a voltage in the range of between 50 V and 150 V. ### Claim 7 (depends on 1) The method according to claim 1, wherein the electro stimulation is carried out with a current in the range of between 0.01 A and 0.4 A. ### Claim 8 (depends on 1) The method according to claim 1, wherein the electro stimulation is carried out with a frequency in the range of between 10 and 200 Hz. ### Claim 9 (depends on 1) The method according to claim 1, wherein said gamma irradiation is administered with an adsorbed radiation dose of between 15 to 35 kGy. ### Claim 10 (depends on 1) The method according to claim 1, wherein the source of the gamma radiation is selected from the group consisting of 60Co, 137Cs, 37Cu, 37Ga, 111In, 192Ir, 99mTc and 170Tm. ### Claim 11 (depends on 1) The method according to claim 1, wherein the method further comprises the step of incubating said blood prior to step c). ### Claim 12 (depends on 1) The method according to claim 1, wherein the method further comprises the step of lyophilization of said serum prior to step d). ### Claim 13 (depends on 1) The method according to claim 1, wherein said blood is arterial and/or venous blood. ### Claim 14 (depends on 1) The method according to claim 1, wherein said blood serum further comprises one or more pharmaceutically acceptable diluents; carriers; excipients, including fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives. ### Claim 15 (depends on 1) The method according to claim 1, wherein the biologically active blood serum is formulated as a syrup, an infusion or injection solution, a tablet, a capsule, a capslet, a lozenge, a liposome, a suppository, a plaster, a band-aid, a retard capsule, a powder, or a slow release formulation. ### Claim 16 (depends on 1) The method according to claim 1, wherein the biologically active blood serum is administered to a subject in need of treatment in an amount ranging from 1 to 500 mg/kg body weight. ### Claim 17 (depends on 1) The method according to claim 1, wherein the biologically active blood serum is administered 24 hours after a stroke. ### Claim 18 (depends on 1) The method according to claim 1, wherein administration is continued for at least 1 week after the stroke. ### Claim 19 (depends on 1) The method according to claim 1, wherein said stroke is selected from an ischemic, thrombotic, embolic, or transient stroke. ### Claim 20 (depends on 1) The method, according to claim 1, wherein the animal is a chicken. ### Claim 21 (depends on 1) The method, according to claim 1, wherein the administration of the biologically active blood serum to the subject results in improved locomotive activity of the subject. ### Claim 22 (depends on 1) The method, according to claim 1, wherein the administration of the biologically active blood serum to the subject results in reduced mortality. ### Claim 23 (depends on 1) The method, according to claim 1, wherein the administration of the biologically active blood serum to the subject results in improved memory of the subject. ### Claim 24 (depends on 1) The method, according to claim 1, wherein administration of the biologically active blood serum to the subject results in improved cognitive function of the subject. ### Claim 25 (depends on 1) The method, according to claim 1, wherein the biologically active blood serum is not administered directly to the brain of the subject. ### Claim 26 (depends on 25) The method, according to claim 25, wherein the blood serum is administered by a route selected from the group consisting of oral, rectal, intragastrical, intravenous, intramuscular, intranasal, intradermal, and subcutaneous.